Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer.

Abstract

Aim: Cetuximab is used for the treatment of RAS wild-type metastatic colorectal cancer patients. Standard administration schedule is once a week; however, the bioequivalence of an every-other-week (EOW) schedule was demonstrated. Methods: We compared a base case scenario of 100% weekly administration to an EOW at 50 or 100%. Medical examinations, patient management and loss of productivity were considered. Results: Base case was estimated at €100.6 million versus €92.8 million and €84.9 million of EOW 50 and 100%, which showed a cost reduction of 8 and 16%, respectively. Indirect costs accounted for 65% in both scenarios. Conclusion: The adoption of an EOW administration schedule of cetuximab reduced direct and indirect costs substantially.

• Authors: Francesco Saverio Mennini, Andrea Marcellusi, Gianluca Fabiano, Lorenza Rimassa, Armando Santoro, Nicola Personeni
• Journal: Future oncology (London, England) (Future Oncol) Vol. 15 Issue 18 Pg. 2107-2112 (Jun 2019) ISSN: 1744-8301 [Electronic] England
• PMID: 31161795 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Immunological
• Cetuximab

Topics

• Antineoplastic Agents, Immunological (administration & dosage, therapeutic use)
• Cetuximab (administration & dosage, therapeutic use)
• Colorectal Neoplasms (diagnosis, drug therapy, epidemiology)
• Drug Administration Schedule
• Female
• Health Care Costs
• Health Expenditures
• Humans
• Incidence
• Male
• Neoplasm Metastasis
• Neoplasm Staging
• Population Surveillance